

Practice-changing trials to watch for in 2018

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Welcome to *Managing Myeloma*. I am Dr. Sagar Lonial. What I want to spend just a moment talking about are some of the potential practice-changing trials that may be coming out in 2018. I think that probably one of the most exciting areas for all of us is the area of CAR-T cells. What we hopefully will begin to see is larger patient populations, or phase 2 expansions of some of those phase 1 studies that have looked so encouraging. We may also begin to see other antibody drug conjugates (ADCs) with monoclonal antibodies. We have again seen updates of the phase 1 trial at ASH 2017, and we are looking forward to potentially phase 2 data on that same target as well. Finally, we will continue to watch the many other molecularly targeted trials, as well as updates from some of those smoldering trials where the activity looks very good, but long-term outcomes are probably the important question. There is a lot on the plate in 2018, and stay tuned for additional updates in myeloma. Thank you very much for viewing this activity.